Invivyd (NASDAQ:IVVD) Given New $1.00 Price Target at D. Boral Capital

Invivyd (NASDAQ:IVVD) had its price objective decreased by D. Boral Capital from $3.00 to $1.00 in a research report released on Monday morning,Benzinga reports. D. Boral Capital currently has a buy rating on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Invivyd in a research note on Thursday, June 26th. One equities research analyst has rated the stock with a Strong Buy rating and three have given a Buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $3.18.

Invivyd Price Performance

NASDAQ:IVVD opened at $0.5597 on Monday. The firm has a market capitalization of $67.24 million, a price-to-earnings ratio of -0.61 and a beta of 0.51. Invivyd has a 1 year low of $0.3546 and a 1 year high of $2.74. The business has a 50 day simple moving average of $0.73 and a 200-day simple moving average of $0.80.

Invivyd (NASDAQ:IVVD) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.08). The company had revenue of $11.79 million during the quarter, compared to the consensus estimate of $23.16 million. Invivyd had a negative net margin of 238.33% and a negative return on equity of 177.89%. As a group, analysts expect that Invivyd will post -1.64 earnings per share for the current fiscal year.

Insider Buying and Selling at Invivyd

In other news, insider Jill Andersen sold 49,402 shares of the stock in a transaction that occurred on Tuesday, August 19th. The stock was sold at an average price of $0.57, for a total value of $28,159.14. Following the sale, the insider directly owned 84,446 shares in the company, valued at approximately $48,134.22. This represents a 36.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold 277,654 shares of company stock valued at $167,215 in the last quarter. Corporate insiders own 25.40% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Catalyst Funds Management Pty Ltd purchased a new position in Invivyd during the 2nd quarter worth $27,000. Vanguard Personalized Indexing Management LLC increased its holdings in Invivyd by 238.6% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company’s stock worth $29,000 after purchasing an additional 28,146 shares during the period. Jane Street Group LLC increased its holdings in Invivyd by 290.5% during the 4th quarter. Jane Street Group LLC now owns 117,432 shares of the company’s stock worth $52,000 after purchasing an additional 87,358 shares during the period. Barclays PLC increased its holdings in Invivyd by 7.8% during the 4th quarter. Barclays PLC now owns 127,180 shares of the company’s stock worth $56,000 after purchasing an additional 9,207 shares during the period. Finally, Nuveen LLC purchased a new position in Invivyd during the 1st quarter worth $65,000. 70.36% of the stock is currently owned by hedge funds and other institutional investors.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.